These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33447944)

  • 1. Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.
    El Hassani M; Caissy JA; Marsot A
    Clin Pharmacokinet; 2021 Apr; 60(4):447-470. PubMed ID: 33447944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
    Marsot A; Guilhaumou R; Riff C; Blin O
    Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.
    Sörgel F; Stephan U; Wiesemann HG; Gottschalk B; Stehr C; Rey M; Böwing HB; Dominick HC; Geldmacher von Mallinckrodt M
    Infection; 1987; 15(5):385-96. PubMed ID: 3319914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Bhatt J; Jahnke N; Smyth AR
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD002009. PubMed ID: 31483853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
    Fusco NM; Toussaint KA; Prescott WA
    Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.